Efficacy and safety of proton therapy versus intensity-modulated radiation therapy in the treatment of head and neck tumors: A systematic review and meta-analysis.
IMRT
adverse events
charged particle radiation
head and neck cancer
meta‐analysis
proton beam radiation
toxicity
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
revised:
19
06
2024
received:
13
05
2024
accepted:
07
07
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
To comprehensively evaluate the therapeutic efficacy and safety when utilizing proton therapy (PT) versus intensity-modulated radiation therapy (IMRT) in head and neck cancer patients. Pubmed, ScienceDirect, Embase, Scopus, and Web of Science were systematically searched for studies on comparative PT and IMRT outcomes. We performed a random effect model meta-analysis to estimate the hazard ratio (HR) and odds ratio (OR) for efficacy and safety outcome variables between PT and IMRT. From 641 identified articles, 11 studies met the inclusion criteria, comprising 3087 patients (606 treated with PT and 2481 with IMRT). On toxicity analysis, PT is associated with decreased acute grade 1 nausea (OR = 0.34, 95% CI: 0.13-0.84, p = 0.02) compared to IMRT. In grade 2 toxicity, PT showed significant advantages over IMRT in mucositis (OR = 0.44, p < 0.0001), dysgeusia (OR = 0.35, p = 0.02), dysphagia (OR = 0.36, p < 0.0001), fatigue (OR = 0.29, p = 0.001), pain (OR = 0.34, p = 0.01), and weight loss (OR = 0.54, p = 0.02). Proton therapy also exhibited increased safety in grade 3 dysphagia incidence (OR = 0.44, p < 0.0001) compared to IMRT. PT demonstrated improved overall survival (OS) compared to IMRT across multiple time points: 1-year OS (HR = 0.43, p = 0.02), 2-year OS (HR = 0.44, p < 0.0001), and 5-year OS (HR = 0.78, p = 0.004). In terms of disease-free survival (DFS), PT also showed improved outcomes at 2-year DFS (HR = 0.65, p = 0.03) and 5-year DFS (HR = 0.81, p = 0.03). Proton therapy demonstrated superior overall survival (OS), disease-free survival (DFS), and better local control rate (LCR) compared to IMRT. The data also showed better safety outcomes in PT patients, particularly when involving grade 2 acute toxicity events.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Sio TT, Lin HK, Shi Q, et al. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient‐reported outcomes. Int J Radiat Oncol Biol Phys. 2016;95(4):1107‐1114. doi:10.1016/j.ijrobp.2016.02.044
Ramaekers BLT, Pijls‐Johannesma M, Joore MA, et al. Systematic review and meta‐analysis of radiotherapy in various head and neck cancers: comparing photons, carbon‐ions and protons. Cancer Treat Rev. 2011;37(3):185‐201. doi:10.1016/j.ctrv.2010.08.004
Romesser PB, Cahlon O, Scher E, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity‐modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016;118(2):286‐292. doi:10.1016/j.radonc.2015.12.008
Moreno AC, Frank SJ, Garden AS, et al. Intensity modulated proton therapy (IMPT)—the future of IMRT for head and neck cancer. Oral Oncol. 2019;88:66‐74. doi:10.1016/j.oraloncology.2018.11.015
Blanchard P, Garden AS, Gunn GB, et al. Intensity‐modulated proton beam therapy (IMPT) versus intensity‐modulated photon therapy (IMRT) for patients with oropharynx cancer—a case matched analysis. Radiother Oncol. 2016;120(1):48‐55. doi:10.1016/j.radonc.2016.05.022
Li X, Kitpanit S, Lee A, et al. Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity‐modulated proton therapy vs intensity‐modulated radiation therapy. JAMA Netw Open. 2021;4(6):e2113205. doi:10.1001/jamanetworkopen.2021.13205
Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005;62(2):494‐500. doi:10.1016/j.ijrobp.2004.09.064
Holliday EB, Kocak‐Uzel E, Feng L, et al. Dosimetric advantages of intensity‐modulated proton therapy for oropharyngeal cancer compared with intensity‐modulated radiation: a case‐matched control analysis. Med Dosim. 2016;41(3):189‐194. doi:10.1016/j.meddos.2016.01.002
Ramesh P, Gu W, Ruan D, Sheng K. Dose and dose rate objectives in Bragg peak and shoot‐through beam orientation optimization for FLASH proton therapy. Med Phys. 2022;49(12):7826‐7837. doi:10.1002/mp.16009
Kim SH, Jeong JH, Ku Y, et al. Range shift verification in spot scanning proton therapy using gamma electron vertex imaging. Med Phys. 2024;51(3):1985‐1996. doi:10.1002/mp.16739
Nguyen ML, Cantrell JN, Ahmad S, Henson C. Intensity‐modulated proton therapy (IMPT) versus intensity‐modulated radiation therapy (IMRT) for the treatment of head and neck cancer: a dosimetric comparison. Med Dosim. 2021;46(3):259‐263. doi:10.1016/j.meddos.2021.02.001
Beddok A, Feuvret L, Noel G, et al. Efficacy and toxicity of proton with photon radiation for locally advanced nasopharyngeal carcinoma. Acta Oncol. 2019;58(4):472‐474. doi:10.1080/0284186X.2018.1543948
Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):407‐421. doi:10.1016/s0360‐3016(02)02754‐2
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Wells G, Shea B, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non‐Randomized Studies in Meta‐Analysis. Ottawa Hospital Research Institute; 2000.
Pollard C, Nguyen TP, Ng SP, et al. Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017;39(10):2079‐2087. doi:10.1002/hed.24872
Zhang W, Zhang X, Yang P, et al. Intensity‐modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiother Oncol. 2017;123(3):401‐405. doi:10.1016/j.radonc.2017.05.006
Kim KN, Harton J, Mitra N, et al. Acute toxicity in patients treated with concurrent chemoradiotherapy with proton versus intensity‐modulated radiation therapy for nonmetastatic head and neck cancers. Head Neck. 2022;44(11):2386‐2394. doi:10.1002/hed.27146
Youssef I, Yoon J, Mohamed N, et al. Toxicity profiles and survival outcomes among patients with nonmetastatic oropharyngeal carcinoma treated with intensity‐modulated proton therapy vs intensity‐modulated radiation therapy. JAMA Netw Open. 2022;5(11):e2241538. doi:10.1001/jamanetworkopen.2022.41538
Yasuda K, Minatogawa H, Dekura Y, et al. Analysis of acute‐phase toxicities of intensity‐modulated proton therapy using a model‐based approach in pharyngeal cancer patients. J Radiat Res. 2021;62(2):329‐337. doi:10.1093/jrr/rraa130
Rwigema JCM, Langendijk JA, Paul van der Laan H, Lukens JN, Swisher‐McClure SD, Lin A. A model‐based approach to predict short‐term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;104(3):553‐562. doi:10.1016/j.ijrobp.2018.12.055
Beddok A, Saint‐Martin C, Krhili S, et al. Curative high‐dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: outcomes and analysis of patterns of failure. Head Neck. 2022;44(11):2452‐2464. doi:10.1002/hed.27153
Chang CL, Lin KC, Chen WM, Shia BC, Wu SY. Comparing the oncologic outcomes of proton therapy and intensity‐modulated radiation therapy for head and neck squamous cell carcinoma. Radiother Oncol. 2024;190:109971. doi:10.1016/j.radonc.2023.109971
Eisbruch A, Dawson LA, Kim HM, et al. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg. 1999;53(3):271‐275.
Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27(7):832‐837. doi:10.1007/s00268‐003‐7105‐6
Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity‐modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys. 2001;49(3):623‐632. doi:10.1016/s0360‐3016(00)01389‐4
van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity‐modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1216‐1224. doi:10.1016/j.ijrobp.2010.05.012
Zhou P, Du Y, Zhang Y, et al. Efficacy and safety in proton therapy and photon therapy for patients with esophageal cancer: a meta‐analysis. JAMA Netw Open. 2023;6(8):e2328136. doi:10.1001/jamanetworkopen.2023.28136
Wang L, Han S, Zhu J, et al. Proton versus photon radiation‐induced cell death in head and neck cancer cells. Head Neck. 2019;41(1):46‐55. doi:10.1002/hed.25357
Yanase M, Kato K, Yoshizawa K, Noguchi N, Kitahara H, Nakamura H. Prognostic value of vascular endothelial growth factors A and C in oral squamous cell carcinoma. J Oral Pathol Med. 2014;43(7):514‐520. doi:10.1111/jop.12167
Ogata T, Teshima T, Kagawa K, et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. 2005;65(1):113‐120.
Chiu KW, Yu TP, Kao YS. A systematic review and meta‐analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer. Oral Oncol. 2024;148:106649. doi:10.1016/j.oraloncology.2023.106649